Processing

Please wait...

Settings

Settings

1. WO1996004556 - LIPOPROTEIN CHOLESTEROL ASSAYS

Publication Number WO/1996/004556
Publication Date 15.02.1996
International Application No. PCT/US1995/009504
International Filing Date 31.07.1995
IPC
G01N 33/537 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
536with immune complex formed in liquid phase
537with separation of immune complex from unbound antigen or antibody
G01N 33/92 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
92involving lipids, e.g. cholesterol
CPC
G01N 2800/044
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
04Endocrine or metabolic disorders
044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
G01N 33/5375
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
536with immune complex formed in liquid phase
537with separation of immune complex from unbound antigen or antibody
5375by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
G01N 33/92
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
92involving lipids, e.g. cholesterol ; , lipoproteins, or their receptors
Applicants
  • HSU, James, T. [US/US]; US
Inventors
  • HSU, James, T.; US
Agents
  • WRAY, James, C. ; Suite 300 1493 Chain Bridge Road McLean, VA 22101, US
Priority Data
08/282,48901.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) LIPOPROTEIN CHOLESTEROL ASSAYS
(FR) DOSAGES DU CHOLESTEROL DE LIPOPROTEINES
Abstract
(EN)
The present invention relates to an assay procedure and/or device for directly measuring VLDL, LDL, HDL as well as apolipoproteins cholesterol in blood plasma and body fluids. The invention provides a method for direct quantitative determination of VLDL, LDL, HDL as well as apolipoproteins cholesterol in a sample of body fluid in which an antibody against the lipoprotein or apolipoprotein is partitioned in one of two phases of an aqueous two-phase system with or without the help of a partitioning enhancer by conjugation. A sample of body fluid, such as blood plasma, is applied to the aqueous two-phase system. After mixing and incubation for a short period of time, the phases are separated by gravity or centrifugation within several minutes. The phase containing the antibody and the targeted lipoprotein or apolipoprotein is removed. The targeted lipoprotein cholesterol is then directly determined by using an enzymatic procedure.
(FR)
La présente invention concerne une procédure de dosage et/ou un appareil permettant de mesurer directement le cholestérol des VLDL, LDL, HDL, et des apolipoprotéines dans le plasma sanguin et dans les liquides organiques. L'invention porte sur un procédé de détermination quantitative directe du cholestérol des VLDL, LDL HDL et apolipoprotéines dans un échantillon de liquide organique dans lequel un anticorps agissant contre la lipoprotéine ou l'apolipoprotéine est fractionné en une ou deux phases d'un système aqueux à deux phases, avec ou sans l'aide d'un activateur de fractionnement par conjugaison. Un échantillon de liquide organique, tel que du plasma sanguin est appliqué au système aqueux à deux phases. Après mélange et incubation de courte durée, les phases subissent une séparation par gravité ou centrifugation pendant plusieurs minutes. La phase contenant l'anticorps et la lipoprotéine ou l'apolipoprotéine ciblées est retirée. Le cholestérol de lipoprotéines ciblé est alors directement déterminé au moyen d'une procédure enzymatique.
Also published as
Latest bibliographic data on file with the International Bureau